NOVN
Price:
$0.0941
Market Cap:
$2.64M
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; W...[Read more]
Industry
Biotechnology
IPO Date
2016-09-21
Stock Exchange
NASDAQ
Ticker
NOVN
According to Novan, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -5749751.00. This represents a change of -120.15% compared to the average of 28.54M of the last 4 quarters.
The mean historical Enterprise Value of Novan, Inc. over the last ten years is 73.65M. The current -5749751.00 Enterprise Value has changed -880.71% with respect to the historical average. Over the past ten years (40 quarters), NOVN's Enterprise Value was at its highest in in the December 2016 quarter at 396.10M. The Enterprise Value was at its lowest in in the December 2015 quarter at -45678000.00.
Average
73.65M
Median
55.18M
Minimum
-720000.00
Maximum
194.87M
Discovering the peaks and valleys of Novan, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 255.60%
Maximum Annual Enterprise Value = 194.87M
Minimum Annual Increase = -27164.97%
Minimum Annual Enterprise Value = -720000.00
Year | Enterprise Value | Change |
---|---|---|
2022 | 23.76M | -14.19% |
2021 | 27.69M | -39.01% |
2020 | 45.41M | -39.87% |
2019 | 75.51M | 255.60% |
2018 | 21.24M | -67.30% |
2017 | 64.95M | -48.93% |
2016 | 127.17M | -18.79% |
2015 | 156.59M | -19.64% |
2014 | 194.87M | -27164.97% |
The current Enterprise Value of Novan, Inc. (NOVN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
32.29M
5-year avg
38.72M
10-year avg
73.65M
Novan, Inc.’s Enterprise Value is less than Tarsus Pharmaceuticals, Inc. (2.02B), greater than LianBio (-66141903.00), less than Aldeyra Therapeutics, Inc. (312.04M), less than Travere Therapeutics, Inc. (2.01B), less than Eton Pharmaceuticals, Inc. (326.12M), less than Tonix Pharmaceuticals Holding Corp. (35.58M), less than Jaguar Health, Inc. (34.57M), less than Acasti Pharma Inc. (14.78M), less than Diffusion Pharmaceuticals Inc. (11.49M), less than iBio, Inc. (15.61M), less than Aditxt, Inc. (12.74M), less than Palisade Bio, Inc. (-2427638.00), less than Plus Therapeutics, Inc. (9.43M), less than Revelation Biosciences, Inc. (-1134396.00), less than Quoin Pharmaceuticals, Ltd. (2.52M), less than Onconova Therapeutics, Inc. (20.79M), less than Adial Pharmaceuticals, Inc. (1.85M), greater than Aeterna Zentaris Inc. (-11767918.00), less than Lyra Therapeutics, Inc. (25.14M), less than Trevi Therapeutics, Inc. (395.25M), greater than SQZ Biotechnologies Company (-35353267.00), less than Protara Therapeutics, Inc. (163.70M), greater than TRACON Pharmaceuticals, Inc. (-6160275.00),
Company | Enterprise Value | Market cap |
---|---|---|
2.02B | $2.13B | |
-66141903.00 | $34.47M | |
312.04M | $324.55M | |
2.01B | $1.64B | |
326.12M | $346.25M | |
35.58M | $57.94M | |
34.57M | $13.57M | |
14.78M | $34.17M | |
11.49M | $8.98M | |
15.61M | $22.42M | |
12.74M | $2.96M | |
-2427638.00 | $5.26M | |
9.43M | $7.25M | |
-1134396.00 | $5.41M | |
2.52M | $5.64M | |
20.79M | $20.90M | |
1.85M | $7.06M | |
-11767918.00 | $17.51M | |
25.14M | $13.62M | |
395.25M | $410.19M | |
-35353267.00 | $12.83M | |
163.70M | $210.72M | |
-6160275.00 | $109.72K |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Novan, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Novan, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Novan, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Novan, Inc. (NOVN)?
What is the 3-year average Enterprise Value for Novan, Inc. (NOVN)?
What is the 5-year average Enterprise Value for Novan, Inc. (NOVN)?
How does the current Enterprise Value for Novan, Inc. (NOVN) compare to its historical average?